Verily Life Sciences Overview
Pro stress-test →Verily Life Sciences is a developer and manufacturer of healthcare tools and devices designed to predict and prevent disease onset and progression. The company offers products including glucose monitors, smart lenses, bioelectronic medicines, surgical robots and precision medicines, enabling consumers to collect health data in timely decision-making and effective interventions.
Strategic Profile
Pro stress-test →In March 2026, the company underwent a significant corporate restructuring, changing its legal name to Verily Health, Inc. and transitioning from an LLC to a corporation following a $300 million investment round, with Alphabet becoming a significant minority investor and relinquishing its controlling stake. The company's primary technology infrastructure, the "Pre" platform, serves as an end-to-end ecosystem that harmonizes fragmented health data; clinical evidence generation solutions facilitate decentralized clinical trials; and care delivery includes virtual care solutions and personalized management programs for chronic conditions through its Onduo brand.
Competitive Landscape
Pro stress-test →Verily's top competitors include iRhythm Technologies, Ginkgo Bioworks, Johnson & Johnson Innovation, and Helix. Verily differentiates through its integrated platform combining hardware (wearables, glucose monitors), software (Pre platform, Project Baseline), and care delivery (Onduo), positioning it against narrower point-solution competitors.
Industry Context
Verily Life Sciences operates in Digital health platforms and precision medicine.
Key facts
Founded: 2015 · Headquarters: South San Francisco, US · Employees: 1,400 · Revenue: Estimated $300M–$500M (based on strategic partnerships and funding activity as of mid-2026)